Pracinostat dihydrochloride
Based on 9 publication(s) in Google Scholar
Pracinostat dihydrochloride is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat dihydrochloride also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM.
For research use only. We do not sell to patients.
- CAS No.: 929016-98-8
- Formula: C20H32Cl2N4O2
- Molecular Weight:431.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Pracinostat dihydrochloride
More- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. [Abstract]
- Drug Des Devel Ther. 2018 Apr 30:12:1009-1017. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Int J Parasitol Drugs Drug Resist. 2026 May 17;31:100649.
- bioRxiv. 2025 Aug 25.
- bioRxiv. 2025 January 15.
- bioRxiv. 2024 Jan 16.
- SSRN. 2023 Jun 20.
- bioRxiv. 2021 Jan 5.
All Beta-lactamase Isoforms
More
Biological Activity
IC50: 40 nM (HDAC10), 43 nM (HDAC3), 47 nM (HDAC5), 49 nM (HDAC1), 56 nM (HDAC4), 70 nM (HDAC9), 93 nM (HDAC11), 96 nM (HDAC2), 137 nM (HDAC7), 140 nM (HDAC8), 1008 nM (HDAC6)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
0.48 μM
Compound: 3, SB939
|
Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay
Antiproliferative activity against human A2780 cells after 96 hrs by celltiter 96 assay
|
[PMID: 21634430] |
| COLO 205 | IC50 |
0.56 μM
Compound: 3, SB939
|
Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay
Antiproliferative activity against human COLO205 cells after 96 hrs by celltiter 96 assay
|
[PMID: 21634430] |
| HCT-116 | IC50 |
0.48 μM
Compound: 3, SB939
|
Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay
Antiproliferative activity against human HCT116 cells after 96 hrs by celltiter 96 assay
|
[PMID: 21634430] |
| MV4-11 | IC50 |
0.1 μM
Compound: 3, SB939
|
Antiproliferative activity against human MV4-11 cells
Antiproliferative activity against human MV4-11 cells
|
[PMID: 21634430] |
| PC-3 | IC50 |
0.34 μM
Compound: 3, SB939
|
Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay
Antiproliferative activity against human PC3 cells after 96 hrs by celltiter 96 assay
|
[PMID: 21634430] |
| PC-3 | IC50 |
0.34 μM
Compound: 3, SB939
|
Antiproliferative activity against human PC3 cells
Antiproliferative activity against human PC3 cells
|
[PMID: 21634430] |
| Ramos | IC50 |
0.14 μM
Compound: 3, SB939
|
Antiproliferative activity against human Ramos cells
Antiproliferative activity against human Ramos cells
|
[PMID: 21634430] |
Chemical Information
-
CAS No. 929016-98-8
-
Molecular Weight 431.40
-
Formula C20H32Cl2N4O2
-
SMILES
CCN(CCN1C2=CC=C(C=C2N=C1CCCC)/C=C/C(NO)=O)CC.Cl.Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
2019 Feb 19;116(8):2961-2966. PMID: 30718431 -
Drug Des Devel Ther
Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). [Abstract]2018 Apr 30:12:1009-1017. PMID: 29750014 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
-
-
-
-
-
Purity & Documentation
References
[1]. Novotny-Diermayr V, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010 Mar;9(3):642-52. [Content Brief]
[2]. Wang H, et al. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile. J Med Chem. 2011 Jul 14;54(13):4694-720. [Content Brief]
[3]. Novotny-Diermayr V, et al. The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML. Blood Cancer J. 2012 May;2(5):e69. [Content Brief]
[4]. Lechner S, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Aug;18(8):812-820. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pracinostat dihydrochloride Related Classifications
HY-105246 Related Classifications
Powered by Bioz